

Express Mail Label No.: EV 317 172 762 US  
Date: August 1, 2003

Attorney Docket No. VPI/00-130-03 CON US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANTS: David Bebbginton, et al.  
CONTINUATION OF: 10/025,164 Examiner: Sudhaker B. Patel  
FILING DATE: HEREWITH GROUP ART UNIT: 1624  
FOR: PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS

August 1, 2003  
Cambridge, Massachusetts 02139

MS Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Pursuant to the duty of disclosure under 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants hereby make of record the documents listed on the Modified Form PTO-1449 (submitted herewith in duplicate). Copies of the listed documents are submitted herewith.

This Information Disclosure Statement is being been filed:

- ☐ within three months of the filing date of the National Application;
- ☐ within three months of the filing date of the entry of the National Stage, as set forth in 37 C.F.R. § 1.491, in an International Application; or
- ☒ before the mailing date of a first Office Action on the merits in the above-identified application.


Accordingly, no fee or certification is required under 37 C.F.R. § 1.97.

Applicants request that these documents: (1) be fully considered by the Examiner during examination of this application, and (2) be printed on any patent that may issue from this application. Applicants also request that a copy of the enclosed form PTO-1449 duly initialed by the Examiner be forwarded to the undersigned with the next communication.

**APPLICANTS: David Bebbington, et al.**

The Commissioner is hereby authorized to charge any fees that may be due, or credit any overpayment to Deposit Account No. 50-0725, Reference No. VPI/00-130-03 CON US.

Respectfully submitted,



Andrea L.C. Robidoux, Reg. No. 47,902

Agent for Applicants

c/o Vertex Pharmaceuticals Incorporated  
130 Waverly Street  
Cambridge, Massachusetts 02139  
Tel: (617) 444- 6731  
Fax: (617) 444-6483

modified Form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Application Number</b>	Not Yet Assigned
	<b>Filing Date</b>	Herewith
	<b>First Named Inventor</b>	David Bebbington
	<b>Group Art Unit</b>	Sudhaker B. Patel
	<b>Examiner Name</b>	1624
	<b>Attorney Docket Number</b>	VPI/00-130-03 CON US

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1*	US 2001/0018436	30-Aug-2001	Tularik Inc.			
	A2*	2002/0065270	05/30/2002	Bristol-Myers Squibb Company			
	A3*	USSN 10/025,164		Vertex Pharmaceuticals Incorporated			19-Dec-2001

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office      Number		Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes      No	
	B1*		WO 02/18346	Pfizer Products, Inc.	07-Mar-2002		
	B2*		WO 00/39101	Astrazeneca UK Limited	06-Jul-2000		
	B3*		WO 00/21955	Zeneca Limited	20-Apr-2000		

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. 10/025,164, filed December 19, 2001, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.